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Abstract: Activation of hepatic stellate cells in response to chronic
inﬂammation represents a crucial step in the development of liver
ﬁbrosis. However, the molecules involved in the interaction between
immune cells and stellate cells remain obscure. Herein, we identify
the chemokine CCL5 (also known as RANTES), which is induced in
murine and human liver after injury, as a central mediator of this
interaction. First, we showed in patients with liver ﬁbrosis that
CCL5 haplotypes and intrahepatic CCL5 mRNA expression were asso-
ciated with severe liver ﬁbrosis. Consistent with this, we detected
Ccl5 mRNA and CCL5 protein in 2 mouse models of liver ﬁbrosis,
induced by either injection of carbon tetrachloride (CCl4) or feeding
on a methionine and choline–deﬁcient (MCD) diet. In these models,
Ccl5–/– mice exhibited decreased hepatic ﬁbrosis, with reduced stel-
late cell activation and immune cell inﬁltration. Transplantation of
Ccl5-deﬁcient bone marrow into WT recipients attenuated liver
ﬁbrosis, identifying inﬁltrating hematopoietic cells as the main
source of Ccl5. We then showed that treatment with the CCL5 recep-
tor antagonist Met-CCL5 inhibited cultured stellate cell migration,
proliferation, and chemokine and collagen secretion. Importantly,
in vivo administration of Met-CCL5 greatly ameliorated liver ﬁbrosis
in mice and was able to accelerate ﬁbrosis regression. Our results
deﬁne a successful therapeutic approach to reduce experimental liver
ﬁbrosis by antagonizing Ccl5 receptors.Journal of Hepatology 20
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Most types of chronic liver disease are characterized by different
degrees of hepatocellular damage, inﬂammatory cell inﬁltrate in
the hepatic parenchyma, and tissue remodeling, ultimately
resulting in progressive ﬁbrosis and cirrhosis. Following repeated
liver injury, a complex interplay between damaged hepatocytes,
inﬂammatory cells, and non-parenchymal cells occurs. Inﬁltrat-
ing inﬂammatory cells at the sites of liver injury are directed
to remove apoptotic cells but in addition they secrete a number
of chemokines that stimulate resident cells such as hepatic stel-
late cells (HSCs). The resulting activated HSCs proliferate and
accumulate in the injured liver, secreting large amounts of extra-
cellular matrix proteins. Therefore, chemokines are currently
considered key drivers of liver ﬁbrogenesis and potential targets
for therapy [1–3]. Chemokines are chemotactic cytokines that
regulate the movement of circulating leukocytes by binding to
their speciﬁc seven-transmembrane domain G-protein-coupled
receptors [4]. According to the presence and position of a con-
served amino-proximal cysteine-containing motif, they are clas-
siﬁed into four subfamilies: CC, CXC, CX3C, and C chemokines
[3]. CC chemokines are the largest family and are deﬁned by
the location of the ﬁrst two cysteine residues in the sequence,
which are adjacent. This group is known also as b-chemokines
or 17q chemokine family, due to a gene cluster on human chro-
mosome 17q11–q32 [4,5]. CCL5, also known as ‘‘regulated upon
activation, normal T-cell expressed, and secreted’’ (RANTES), is a
small CC chemokine that has powerful chemoattracting proper-
ties toward T cells, dendritic cells, eosinophils, NK cells, mast
cells, and basophils. CCL5 is produced by different cell types
including T cells, platelets, macrophages, endothelial cells, and
ﬁbroblasts and exerts its actions by binding to three receptors
(CCR1, CCR3, and CCR5) [6]. A growing body of evidence indi-
cates that RANTES is involved in a variety of inﬂammatory con-
ditions including atherosclerosis and obesity, which share
common pathophysiological pathways with liver diseases [7,8].
Pharmaceutical companies have recently developed RANTES
inhibitors/CCR5 antagonists, which are currently being evaluated
in several inﬂammatory diseases. Moreover, because CCR5 is
involved in HIV entry to target cells, CCR5 antagonists have been
successfully tested in phase III studies in patients with HIV
infection [9].11 vol. 55 j 936–938
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Fig. 1. Implication of RANTES in the pathogenesis of liver ﬁbrosis due to HCV infection. HCV entries hepatocytes and is cleaved into different proteins with biological
actions (core, NS3, NS5, etc.). Some of these proteins are expressed in the membrane of hepatocytes together with MHC-I and MHC-II molecules. Moreover, infected
hepatocytes secrete inﬂammatory cytokines. Both actions activate and recruit T-lymphocytes that secrete mediators including RANTES. Neighboring biliary cells and non-
parenchymal cells (hepatic stellate cells – HSC and Kupffer cells) become activated and secrete free radicals and ﬁbrogenic and inﬂammatory mediators. The inﬂammatory
milieu activates resident HSC into myoﬁbroblastic cells. These latter cells express CCR5 and secrete RANTES. Paracrine and autacrine actions of RANTES in HSCs stimulate
intracellular signaling pathways leading to increased collagen synthesis, impaired collagen degradation and secretion of further inﬂammatory mediators. These actions lead
to progressive ﬁbrosis and persistent liver inﬂammation. The use of new RANTES receptor antagonists (e.g. Met-CCL5) could block the pathogenic effects of RANTES and
attenuate the progression of liver ﬁbrosis.
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Experimental and human evidence indicate that RANTES is
implicated in hepatic wound healing response to chronic injury.
An initial study demonstrated that RANTES is expressed and
secreted by activated HSCs, which are the main collagen-produc-
ing cells in the injured liver. In these cells, RANTES induces
migration, proliferation, and ﬁbrogenic properties [10]. Moreover,
studies in experimental and human liver ﬁbrosis convincingly
showed that the CCL5/CCR5 axis is an important system in the
hepatic would healing response. This axis is over-expressed in
different models of liver ﬁbrosis and in patients with chronic liver
diseases such as chronic HCV infection (Fig. 1). Importantly, dele-
tion of CCR5 markedly attenuated liver ﬁbrosis in mice [11]. The
underlying mechanisms include modulation of inﬁltration of T
lymphocytes and bone-marrow derived cells and reduced HSCs
activation. Finally, recent data suggest that RANTES could be
involved in the chemotaxis of progenitor cells during hepatic
ﬁbrogenesis and tissue repair [12].
In the paper by Berres et al. [6], the authors expanded these
previous data by performing a multi-approach study demonstrat-
ing that RANTES is a major driver of inﬂammation and ﬁbrosis in
chronic liver injury. First, a genetic analysis indicated that RAN-
TES gene variations inﬂuence the degree of liver ﬁbrosis in
patients with chronic hepatitis C. The haplotype CCL5_H3 was
found more prevalent in patients with advanced ﬁbrosis com-
pared with those with mild ﬁbrosis. Second, RANTES mRNA and
protein expression were up-regulated in two experimental mod-
els of liver ﬁbrosis as well as in patients with advanced HCV-
induced ﬁbrosis. Third, they demonstrated that genetic ablation
of RANTES results in attenuated liver ﬁbrosis in mice subjected
to two experimental models of liver ﬁbrosis. Absence of RANTES
was associated with reduced HSCs activation and immune cell
inﬁltration in the injured liver. By studying bone marrow chime-
ric mice, they provide evidence that immune cells are the main
source of RANTES in liver ﬁbrogenesis, while resident HSCs are
probably a target cell type for this chemokine. Finally, the authors
tested a recently developed RANTES receptor antagonist (Met-
CCL5) in vitro and in vivo. Met-CCL5 inhibited the proliferation
and migration of cultured HSCs as well as chemokine secretion
and collagen synthesis. Furthermore, RANTES inhibition attenu-
ated the progression of liver ﬁbrosis in mice treated with CCl4
and was able to accelerate ﬁbrosis regression after cessation of
liver injury.
The study by Berres et al. provides convincing pre-clinical
evidence that RANTES inhibition is a promising approach to
treat chronic liver diseases. However, there are several issues
that deserve further attention. The effect of RANTES inhibition
on regression of liver ﬁbrosis was only mild and additional
studies using different experimental models are needed. Also,
the expression of RANTES and its receptors in alcoholic liver
disease, which is mainly driven by polymorphonuclear cells,
should be explored. Because the authors propose that RANTES
is involved in disease progression in chronic hepatitis C, it
seems pertinent to explore whether RANTES inhibition modu-
lates HCV cell cycle, replication, and pathogenic effects. For this
purpose, in vitro replicon systems and transgenic mice are
available experimental tools.
Additional studies are also required to better delineate the
role of RANTES in liver ﬁbrogenesis and its potential as a target
for therapy in humans. Translational studies in different degrees
and types of chronic liver diseases should identify the speciﬁc cell
origin of RANTES. The pathogenic effects of RANTES in mediating938 Journal of Hepatology 201hepatocellular injury, endothelial dysfunction, immune distur-
bances, and collagen synthesis are largely unknown and deserve
further investigation. Importantly, future studies should investi-
gate the involvement of CCL5/CCR5 axis in liver regeneration
and cancer development. And ﬁnally, carefully-designed experi-
mental studies should explore the potential side effects of contin-
uous inhibition in RANTES and/or its receptors in animals with
chronic liver injury. In this line, a recent report [13] indicates that
lack of CCR5 promotes murine fulminant liver failure by prevent-
ing the apoptosis of activated CD1d-restricted NKT cells. This
study suggests that prolonged manipulation of chemokine recep-
tors may result in tissue damage instead of resolution of inﬂam-
mation. Another potential side effect of prolonged RANTES
inhibition is inducing immunosuppression. This is particularly
important in patients with liver cirrhosis, acute-on-chronic liver
disease, and patients with alcoholic liver disease, who are prone
to develop severe bacterial infections due to impaired immune
defense.
Although chemokines including RANTES are currently consid-
ered an appealing family of molecular targets to develop antiﬁb-
rotic therapies, all these biological and clinical parameters should
be carefully considered before testing this type of drugs in
patients with chronic liver diseases.Conﬂict of interest
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